These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 2304224)
1. Researchers follow varied molecular paths toward better control of organ rejection. Goldsmith MF JAMA; 1990 Mar; 263(9):1184, 1187. PubMed ID: 2304224 [No Abstract] [Full Text] [Related]
2. Mycophenolate approval provides new option for organ-rejection prevention. Am J Health Syst Pharm; 1995 Oct; 52(19):2078. PubMed ID: 8535937 [No Abstract] [Full Text] [Related]
3. The influence of RS-61443 on antibody-mediated rejection. Knechtle SJ; Wang J; Burlingham WJ; Beeskau M; Subramanian R; Sollinger HW Transplantation; 1992 Mar; 53(3):699-701. PubMed ID: 1549873 [No Abstract] [Full Text] [Related]
4. Clinical and experimental immunosuppression. Castillo Lugo JA Bol Asoc Med P R; 1995; 87(5-6):106-8. PubMed ID: 8573248 [No Abstract] [Full Text] [Related]
5. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Morris RE; Hoyt EG; Murphy MP; Eugui EM; Allison AC Transplant Proc; 1990 Aug; 22(4):1659-62. PubMed ID: 2389428 [No Abstract] [Full Text] [Related]
6. New antirejection drugs anticipated. Randall T JAMA; 1990 Sep; 264(10):1225. PubMed ID: 1696999 [No Abstract] [Full Text] [Related]
7. Mycophenolate mofetil. Bell J; Ross K ANNA J; 1996 Aug; 23(4):409-10, 413. PubMed ID: 8900688 [No Abstract] [Full Text] [Related]
8. RS-61443: a new immunosuppressive agent. Young CJ; Sollinger HW Transplant Proc; 1994 Dec; 26(6):3144-6. PubMed ID: 7998096 [No Abstract] [Full Text] [Related]
9. Is mycophenolate mofetil better than azathioprine in organ transplantation? Ruggenenti P; Remuzzi G Transplantation; 2006 Nov; 82(9):1242-3. PubMed ID: 17102781 [No Abstract] [Full Text] [Related]
11. The case of azathioprine versus mycophenolate. Do different drugs really cause different transplant outcomes? Craig JC; Webster AC; McDonald SP Transplantation; 2009 Mar; 87(6):803-4. PubMed ID: 19300180 [No Abstract] [Full Text] [Related]
16. Therapeutic drug monitoring of mycophenolates: why make simple things complicated? Kuypers DR; van Gelder T Transplant Rev (Orlando); 2011 Apr; 25(2):45-6. PubMed ID: 21477747 [No Abstract] [Full Text] [Related]
17. Heterotopic rat intestinal transplantation: effect of cyclosporine and RS-61443 on graft-vs-host disease and rejection. D'Alessandro AM; Rankin MA Transplant Proc; 1994 Jun; 26(3):1611-2. PubMed ID: 8030056 [No Abstract] [Full Text] [Related]
18. Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas' heart transplant recipients. Bestetti RB; Souza TR; Lima MF; Theodoropoulos TA; Cordeiro JA; Burdmann EA Transplantation; 2007 Aug; 84(3):441-2. PubMed ID: 17700175 [No Abstract] [Full Text] [Related]
19. Treatment of severe acute vascular rejection in a renal allograft with mycophenolate mofetil and high dose steroids. Lafferty ME; Lang S; McGregor E; Henderson IS; Jones MC Scott Med J; 1997 Jun; 42(3):79-80. PubMed ID: 9351121 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new immunosuppressant, CAM, on small bowel transplantation in rats. Sawada H; Kaihara S; Egawa H; Inomata Y; Tanaka K; Yamaoka Y Transplant Proc; 1996 Oct; 28(5):2512-3. PubMed ID: 8907928 [No Abstract] [Full Text] [Related] [Next] [New Search]